AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35109763
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg vitamin B6 daily
Trial: 37589610
Drug: Patient-activation tool
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-activation tool for intensification of medications for chronic heart failure
Trial: 32739670
Drug: Transitional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transitional care intervention including risk assessment for early readmission, health education from admission to predischarge, individualized discharge planning, and weekly telephone follow-up for one month and WeChat follow-up postdischarge.
Trial: 32994020
Drug: Resveratrol/ethanol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol/ethanol 10 mg/mL
Trial: 32994020
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 mg/mL resveratrol/ethanol)
Trial: 35691791
Drug: Intranasal gonadorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal gonadorelin treatment
Trial: 35691791
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no gonadorelin treatment)
Trial: 32622768
Drug: Novel penile
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel penile splint (Early Traction Therapy - ETT) applied post-surgery
Trial: 33250386
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg mint nicotine gum
Trial: 35417188
Drug: Bifidobacterium infantis
RxNorm normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium infantis (EVC001) administered daily for 28 days
Trial: 33196773
Drug: Withholding standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding standard intravenous empirical antibiotics for 48 hours after birth
Trial: 33196773
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous empirical antibiotics for 48 hours after birth
Trial: 35079088
Drug: 3CLpro inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3CLpro inhibitor PF-07321332
Trial: 34601410
Drug: Traffic-polluted road
RxNorm normalized name: Road to Wellness KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traffic-polluted road walking treatment
Trial: 34601410
Drug: Traffic-free park
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traffic-free park walking treatment
Trial: 32887557
Drug: 2 L/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L/min O2
Trial: 32359741
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day curcuminoids
Trial: 32359741
Drug: 50,000 IU/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU/week vitamin D3 plus 500 mg/day curcuminoids
Trial: 34871182
Drug: CERC-002 (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERC-002 (human LIGHT-neutralizing antibody)
Trial: 32722015
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (EG) - dairy preparation enriched in calcium, vitamin D, vitamin K, vitamin C, zinc, magnesium, L‐leucine and probiotic (Lactobacillus plantarum 3547) consumed daily for 24 weeks
Trial: 36280804
Drug: Opioid-free anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-free anesthesia (OFA) regimen including IV magnesium sulfate, lidocaine, ketamine, dexamethasone, propofol, rocuronium, isoflurane, and continuous infusion of magnesium sulfate, ketamine, and clonidine
Trial: 36263942
Drug: L-theanine 200
RxNorm normalized name: L-theanine 200 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine 200 mg to 400 mg
Trial: 34514770
Drug: Intrauterine infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine infusion of PRP (0.5CC, contained platelet 4-5 times more than a peripheral blood sample, performed 48 hours before blastocyst transfer)
Trial: 32963066
Drug: Maternally administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternally administered malnutrition monitoring system (MAMMS) with SMS prompts for MUAC measurement.
Trial: 34836277
Drug: Capsule containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing spray-dried powder from pineapple juice broth fermented with Lactobacillus paracasei IJH-SONE68, taken daily for 12 weeks
Trial: 34836277
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken daily for 12 weeks
Trial: 34836277
Drug: Capsule containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing spray-dried powder from pineapple juice broth fermented with Lactobacillus paracasei IJH-SONE68
Trial: 35552172
Drug: Cardiac rehabilitation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac rehabilitation combined with routine treatment
Trial: 35552172
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment only (positive control group)
Trial: 36459138
Drug: High-dose erythropoietin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose erythropoietin (2000 units/kg body weight)
Trial: 32558052
Drug: Mirabegron (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (200 mg one dose p.o.)
Trial: 35485627
Drug: Telephone follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone follow-up (four 30-minute sessions twice a week for a month)
Trial: 34989412
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal anesthetic (TNA) - viscous lidocaine
Trial: 33915390
Drug: No endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endovascular therapy (no-EVT)
Trial: 32003938
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg + amlodipine 10 mg
Trial: 33773639
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control medication list app (control arm)
Trial: 36138363
Drug: i-gel combined
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel combined with flexible bronchoscopy-guided intubation
Trial: 36464680
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (APP+DOC)
Trial: 36464680
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual group (TAU)
Trial: 33331850
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (IOL and CL)
Trial: 35896083
Drug: Relefact LHRH®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relefact LHRH® (100 μg/m2)
Trial: 32358357
Drug: Baseline ALT
RxNorm normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline ALT >133 U/L
Trial: 35332737
Drug: Non-invasive bi-level
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive bi-level positive airway pressure (BiPAP) ventilation in treatment group 1
Trial: 35332737
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) oxygen therapy in treatment group 2
Trial: 35332737
Drug: Treatment groups
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment groups (1 and 2)
Trial: 33602198
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) using laser diode 940 nm
Trial: 34413118
Drug: Native human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Native human insulin (HI)
Trial: 33253354
Drug: Verubecestat (BACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat (BACE inhibitor)
Trial: 35834528
Drug: High-dose micronutrient-antioxidant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose micronutrient-antioxidant supplement
Trial: 35834528
Drug: RDA supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDA supplement
Trial: 32720121
Drug: NACT (Neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACT (Neoadjuvant Chemotherapy)
Trial: 35763437
Drug: Snail secretion
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snail secretion filtrate, Calendula officinalis, and Glycyrrhiza glaba root extract combination serum (SCGS)
Trial: 35763437
Drug: SCGS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCGS with concurrent acne treatments
Trial: 35217746
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral hygiene care administered every 24 hours
Trial: 35217746
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral hygiene care
Trial: 34608929
Drug: Tirzepatide (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (1, 5, 10, 15 mg)
Trial: 33370506
Drug: Voice Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice Therapy (VT)
Trial: 32577737
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (resistance‐band and Biomechanical Ankle Platform System)
Trial: 33608048
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg tianeptine
Trial: 32717713
Drug: Adjunctive brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive brivaracetam (BRV) 100 and 200 mg/day
Trial: 35263517
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of standard first-line antituberculosis treatment
Trial: 35263517
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of standard first-line antituberculosis treatment
Trial: 35263517
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of treatment
Trial: 34004483
Drug: Evinacumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evinacumab (15 mg/kg intravenously once monthly)
Trial: 34455435
Drug: Active oil
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oil (high-dose, purified omega-3 fatty acids) mimicking REDUCE-IT
Trial: 34455435
Drug: Active oil
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oil (high-dose, purified omega-3 fatty acids) mimicking STRENGTH
Trial: 36131603
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg bid
Trial: 35725494
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine continuous parasternal block at 7 ml/hour for 72 hours
Trial: 35285173
Drug: liraglutide 1.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg
Trial: 35285173
Drug: liraglutide 0.9 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 0.9 mg
Trial: 35613822
Drug: Sintilimab 200
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200 mg plus bevacizumab 15 mg/kg every 3 weeks
Trial: 34652968
Drug: Standard five-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles
Trial: 34652968
Drug: Experimental therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapy with five cycles of vincristine, topotecan, and cyclophosphamide (VTC) within the 17 cycles (regimen B)
Trial: 32747497
Drug: BNP infusion
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP infusion (0.006 μg/kg/min for 72 hours)
Trial: 33798307
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between acupuncture and sham acupuncture groups after treatment.
Trial: 34297268
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice daily for 10 days
Trial: 33320286
Drug: Hypofractionated RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated RT with sequential boost (HFseq)
Trial: 33320286
Drug: Normofractionated RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normofractionated RT with sequential boost (NFseq)
Trial: 35190414
Drug: SFP10‐14 intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFP10‐14 intervention comprising seven weekly sessions
Trial: 616708360
Drug: Khanda Pippali
RxNorm normalized name: Chanda Root
DrugBank: Angelica archangelica root (DB14283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Khanda Pippali Avaleha (10 g orally for 60 days)
Trial: 616708360
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg once a day for 60 days, empty stomach)
Trial: 34465402
Drug: Direct maxillary
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct maxillary sinus saline irrigation with systemic antibiotics and topical sprays (n = 24)
Trial: 34465402
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy alone (n = 15)
Trial: 32090788
Drug: Rhodiola capsule
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola capsule (0.6 g/day) combined with sertraline
Trial: 32090788
Drug: Rhodiola capsule
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola capsule (0.3 g/day) combined with sertraline
Trial: 32090788
Drug: Sertraline with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline with two placebos (0.6 g/day)
Trial: 33653757
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose vitamin D supplementation (50,000 IU cholecalciferol) taken monthly for 2 years, with an initial loading dose of 500,000 IU cholecalciferol.
Trial: 35025149
Drug: Acupuncture (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (specific details on dosage and duration are not available)
Trial: 34959924
Drug: Spinach extract
RxNorm normalized name: spinach extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinach extract supplementation (4 × 500 mg capsules/day; total 2 g per day) combined with moderate-intensity training (1 h session/3 times a week)
Trial: 32196623
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg aspirin
Trial: 36414575
Drug: Lipid-based nutritional
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutritional supplement (LNS)
Trial: 35283411
Drug: Dual group
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual group (aspirin plus cilostazol)
Trial: 35332289
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab therapy
Trial: 34275830
Drug: Propofol dosing
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol dosing based on total body weight (TBW)
Trial: 32044943
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (vancomycin or daptomycin + antistaphylococcal β-lactam)
Trial: 32044943
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (vancomycin or daptomycin alone)
Trial: 32044943
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (excluding dialysis patients)
Trial: 32044943
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (excluding dialysis patients)
Trial: 32815921
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg daily for 12 weeks
Trial: 616120383
Drug: Anti-VEGF injections
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF injections
Trial: 33858718
Drug: MMRV (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV (two doses)
Trial: 33858718
Drug: MMR +
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR + V (one dose of MMR followed by one dose of V)
Trial: 33858718
Drug: MMR (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR (control group, two doses)
Trial: 33803814
Drug: HAplus gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAplus gel (Aminogam gel®) applied to gingival tissue post-extraction
Trial: 33803814
Drug: HAplus gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAplus gel enriched with vitamins C and E (TEST groups)
Trial: 32144829
Drug: Preoperative pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative pelvic floor muscle training (PFMT) daily from inclusion to surgery (n=81)
Trial: 35578230
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (maximum of 6 sessions within 6 weeks, including spinal manipulation/mobilization, massage, and stretching)
Trial: 33629490
Drug: Haemoglobin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin levels of 70-89 g/l at 6+0 - 13+6 weeks
Trial: 36482258
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg NMN
Trial: 36482258
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg NMN
Trial: 36482258
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg NMN
Trial: 36482258
Drug: NMN (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMN (all doses)
Trial: 36482258
Drug: HOMA-IR (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOMA-IR (all NMN doses)
Trial: 33772133
Drug: PRP +
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP + CaCl2 solution
Trial: 34222540
Drug: Benson's relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson's relaxation technique (listened to a voice containing relaxation technique twice a day for eight weeks)
Trial: 33515539
Drug: Ceritinib +
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib + AKT inhibitors (Capivasertib and Afuresertib)
Trial: 33515539
Drug: AKT inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKT inhibitors (Capivasertib and Afuresertib) alone
Trial: 33121605
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (AP) prescribing for invasive dental procedures in high-risk patients
Trial: 33121605
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (AP) prescribing for invasive dental procedures in moderate-risk patients
Trial: 33121605
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (AP) prescribing for invasive dental procedures in low or unknown risk patients
Trial: 36087590
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg orally every 12 h for 7 days followed by 4 mg orally every 12 h for 7 days
Trial: 32479903
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with chloro-aluminum phthalocyanine (AlClPc) and scaling and root planning (SRP)
Trial: 35611518
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times weekly heparin flushing
Trial: 35611518
Drug: Daily heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily heparin flushing (standard of care)